A controlled study of amniotic membrane transplantation for acute Pseudomonas keratitis.
OBJECTIVE
To evaluate the efficacy of amniotic membrane transplantation (AMT) to improve the outcomes of acute Pseudomonas keratitis as compared with a control group.


METHODS
Prospective interventional case series with retrospective controls.


METHODS
We studied 14 eyes with Pseudomonas keratitis as the AMT group and 11 eyes with Pseudomonas keratitis as the control group.


METHODS
Eyes in the AMT group were treated with antibiotic therapy followed by single-layer AMT at 2 to 3 days. Eyes in the control group received only antibiotic therapy. Patients were followed for 11.1 ± 2.4 months.


RESULTS
In the AMT group, pain significantly decreased from a mean score of 2.4 ± 0.5 preoperatively to 1.1 ± 0.9 at day 2 postoperatively (p < 0.001). Corneal epithelial defects healed completely within 13.2 ± 2.6 days in the AMT group compared with 15.5 ± 3.4 days in the control group (p = 0.07). At final follow-up visits, the sizes of corneal opacity and deep neovascularization were not different between the 2 groups. However, the mean score for density of the corneal opacity was significantly less in the AMT group compared with the control group (2.1 ± 0.4 vs 2.5 ± 0.7, respectively, p = 0.04). Although the best corrected visual acuity using hard contact lenses was not different between the 2 groups, uncorrected visual acuity was better in the AMT group (0.45 ± 0.22 logMAR) than in the control group (0.71 ± 0.32 logMAR, p = 0.03). No patient in either group developed significant corneal thinning or perforation.


CONCLUSIONS
AMT in acute Pseudomonas keratitis was associated with immediate pain relief, less density of the final corneal opacity, and better uncorrected visual acuity at the final follow-up visit.
Farabi Eye Hospital, Eye Research Center, Tehran University of Medical Sciences, Tehran, Islamic Republic of Iran. akheirkh@yahoo.com
Ahmad
A
Kheirkhah
Ali
A
Tabatabaei
Mehdi Khodaparast
MK
Zavareh
Alireza
A
Khodabandeh
Mehrdad
M
Mohammadpour
Vadrevu K
VK
Raju
D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000650:Amnion / Q000637:transplantation*; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D001684:Biological Dressings; D002442:Ceftazidime / Q000627:therapeutic use; D003318:Corneal Opacity / Q000503:physiopathology; D003320:Corneal Ulcer / Q000188:drug therapy / Q000382:microbiology / Q000601:surgery*; D015818:Eye Infections, Bacterial / Q000188:drug therapy / Q000382:microbiology / Q000601:surgery*; D058447:Eye Pain / Q000503:physiopathology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D011552:Pseudomonas Infections / Q000188:drug therapy / Q000382:microbiology / Q000601:surgery*; D012189:Retrospective Studies; D016896:Treatment Outcome; D014792:Visual Acuity / Q000502:physiology; D055815:Young Adult
D000900:Anti-Bacterial Agents; D002442:Ceftazidime